Key result
Low-dose vasopressin lacks reported quantitative data for maintaining arterial pressure in severe heart failure.
Why the study?
PDE III inhibitors induce vasodilation and hypotension in patients with severe heart failure, and a specific antagonist for this vascular action could be clinically useful.
Does low-dose vasopressin maintain arterial pressure in patients with severe congestive heart failure receiving PDE III inhibitors?
Population
Patients with severe congestive heart failure receiving PDE III inhibitors
Comparison
Low-dose vasopressin vs no vasopressin
Design
Other
Authors
Loading...
No quantitative results available to inform vasopressin use; leaves open prospective evaluation in severe HF with PDE III inhibitor hypotension.
Does low-dose vasopressin maintain arterial pressure in patients with severe congestive heart failure receiving PDE III inhibitors?
The study investigates whether low-dose vasopressin can maintain arterial pressure in severe heart failure patients experiencing PDE III inhibitor-induced hypotension.
Gold et al. (2000) studied Severe congestive heart failure with milrinone-induced hypotension. Vasopressin was evaluated on Maintenance of arterial pressure. The efficacy of low-dose vasopressin for maintaining arterial pressure in severe heart failure was examined, but no quantitative results are reported in the abstract.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: